Switch theme
Sign up to access all valuation multiples
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
2005
136
LTM Revenue $79.0M
LTM EBITDA -$113M
$178M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AnaptysBio has a last 12-month revenue of $79.0M and a last 12-month EBITDA of -$113M.
In the most recent fiscal year, AnaptysBio achieved revenue of $91.3M and an EBITDA of -$92.7M.
AnaptysBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AnaptysBio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $17.2M | $91.3M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$143M | -$92.7M | XXX | XXX | XXX |
| EBITDA Margin | -834% | -102% | XXX | XXX | XXX |
| Net Profit | -$129M | -$164M | XXX | XXX | XXX |
| Net Margin | -750% | -179% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, AnaptysBio's stock price is $18.
AnaptysBio has current market cap of $548M, and EV of $178M.
See AnaptysBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $178M | $548M | XXX | XXX | XXX | XXX | $-5.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, AnaptysBio has market cap of $548M and EV of $178M.
AnaptysBio's trades at 2.3x LTM EV/Revenue multiple, and -1.6x LTM EBITDA.
Analysts estimate AnaptysBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for AnaptysBio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $178M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.9x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAnaptysBio's NTM/LTM revenue growth is -32%
AnaptysBio's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $1.5M for the same period.
Over next 12 months, AnaptysBio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate AnaptysBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for AnaptysBio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 432% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -102% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -35% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -133% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 46% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 179% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 226% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AnaptysBio acquired XXX companies to date.
Last acquisition by AnaptysBio was XXXXXXXX, XXXXX XXXXX XXXXXX . AnaptysBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was AnaptysBio founded? | AnaptysBio was founded in 2005. |
| Where is AnaptysBio headquartered? | AnaptysBio is headquartered in United States of America. |
| How many employees does AnaptysBio have? | As of today, AnaptysBio has 136 employees. |
| Who is the CEO of AnaptysBio? | AnaptysBio's CEO is Mr. Daniel R. Faga. |
| Is AnaptysBio publicy listed? | Yes, AnaptysBio is a public company listed on NAS. |
| What is the stock symbol of AnaptysBio? | AnaptysBio trades under ANAB ticker. |
| When did AnaptysBio go public? | AnaptysBio went public in 2017. |
| Who are competitors of AnaptysBio? | Similar companies to AnaptysBio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of AnaptysBio? | AnaptysBio's current market cap is $548M |
| What is the current revenue of AnaptysBio? | AnaptysBio's last 12-month revenue is $79.0M. |
| What is the current EBITDA of AnaptysBio? | AnaptysBio's last 12-month EBITDA is -$113M. |
| What is the current EV/Revenue multiple of AnaptysBio? | Current revenue multiple of AnaptysBio is 2.3x. |
| What is the current EV/EBITDA multiple of AnaptysBio? | Current EBITDA multiple of AnaptysBio is -1.6x. |
| What is the current revenue growth of AnaptysBio? | AnaptysBio revenue growth between 2023 and 2024 was 432%. |
| Is AnaptysBio profitable? | Yes, AnaptysBio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
